Actavis sells infrastructure to India's Aruobindo
Generics firm Actavis announced Friday that it was selling its pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products, marketing authorizations and dossier license rights to India's Aurobindo Pharma, which has been on a path of expanding its European footprint.
Friday's announcement follows Bloomberg's report that Actavis is looking to extricate itself from China. CEO Paul Bisaro told Bloomberg at the JP Morgan Healthcare conference that China's business climate is too difficult to continue to operate in. “It wasn't worth the aggravation, the frustration or the concern.”